Kevin J Pridham1,2, Lamvy Le1,3, Sujuan Guo1, Robin T Varghese1, Sarah Algino1, Yanping Liang1, Renee Fajardin1, Cara M Rodgers4, Gary R Simonds4, Deborah F Kelly1,3,5,6, Zhi Sheng1,3,7,5. 1. Virginia Tech Carilion Research Institute, Virginia Tech, Roanoke, Virginia. 2. Graduate Program in Translational Biology, Medicine, and Health, Virginia Tech, Blacksburg, Virginia. 3. Virginia Tech Carilion School of Medicine, Virginia Tech, Roanoke, Virginia. 4. Department of Neurosurgery, Carilion Clinic, Roanoke, Virginia. 5. Faculty of Health Science, Virginia Tech, Blacksburg, Virginia. 6. Department of Biological Sciences, Virginia Tech, Blacksburg, Virginia. 7. Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, Virginia.
Abstract
Background: Glioblastoma (GBM) is difficult to treat. Phosphoinositide 3-kinase (PI3K) is an attractive therapeutic target for GBM; however, targeting this pathway to effectively treat GBM is not successful because the roles of PI3K isoforms remain to be defined. The aim of this study is to determine whether PIK3CB/p110β, but not other PI3K isoforms, is a biomarker for GBM recurrence and important for cell survival. Methods: Gene expression and clinical relevance of PI3K genes in GBM patients were analyzed using online databases. Expression/activity of PI3K isoforms was determined using immunoblotting. PI3K genes were inhibited using short hairpin RNAs or isoform-selective inhibitors. Cell viability/growth was assessed by the MTS assay and trypan blue exclusion assay. Apoptosis was monitored using the caspase activity assay. Mouse GBM xenograft models were used to gauge drug efficacy. Results: PIK3CB/p110β was the only PI3K catalytic isoform that significantly correlated with high incidence rate, risk, and poor survival of recurrent GBM. PIK3CA/p110α, PIK3CB/p110β, and PIK3CD/p110δ were differentially expressed in GBM cell lines and primary tumor cells derived from patient specimens, whereas PIK3CG/p110γ was barely detected. PIK3CB/p110β protein levels presented a stronger association with the activities of PI3K signaling than other PI3K isoforms. Blocking p110β deactivated PI3K signaling, whereas inhibition of other PI3K isoforms had no effect. Specific inhibitors of PIK3CB/p110β, but not other PI3K isoforms, remarkably suppressed viability and growth of GBM cells and xenograft tumors in mice, with minimal cytotoxic effects on astrocytes. Conclusions: PIK3CB/p110β is a biomarker for GBM recurrence and selectively important for GBM cell survival.
Background: Glioblastoma (GBM) is difficult to treat. Phosphoinositide 3-kinase (PI3K) is an attractive therapeutic target for GBM; however, targeting this pathway to effectively treat GBM is not successful because the roles of PI3K isoforms remain to be defined. The aim of this study is to determine whether PIK3CB/p110β, but not other PI3K isoforms, is a biomarker for GBM recurrence and important for cell survival. Methods: Gene expression and clinical relevance of PI3K genes in GBM patients were analyzed using online databases. Expression/activity of PI3K isoforms was determined using immunoblotting. PI3K genes were inhibited using short hairpin RNAs or isoform-selective inhibitors. Cell viability/growth was assessed by the MTS assay and trypan blue exclusion assay. Apoptosis was monitored using the caspase activity assay. Mouse GBM xenograft models were used to gauge drug efficacy. Results:PIK3CB/p110β was the only PI3K catalytic isoform that significantly correlated with high incidence rate, risk, and poor survival of recurrent GBM. PIK3CA/p110α, PIK3CB/p110β, and PIK3CD/p110δ were differentially expressed in GBM cell lines and primary tumor cells derived from patient specimens, whereas PIK3CG/p110γ was barely detected. PIK3CB/p110β protein levels presented a stronger association with the activities of PI3K signaling than other PI3K isoforms. Blocking p110β deactivated PI3K signaling, whereas inhibition of other PI3K isoforms had no effect. Specific inhibitors of PIK3CB/p110β, but not other PI3K isoforms, remarkably suppressed viability and growth of GBM cells and xenograft tumors in mice, with minimal cytotoxic effects on astrocytes. Conclusions: PIK3CB/p110β is a biomarker for GBM recurrence and selectively important for GBM cell survival.
Authors: T Sasaki; J Irie-Sasaki; R G Jones; A J Oliveira-dos-Santos; W L Stanford; B Bolon; A Wakeham; A Itie; D Bouchard; I Kozieradzki; N Joza; T W Mak; P S Ohashi; A Suzuki; J M Penninger Journal: Science Date: 2000-02-11 Impact factor: 47.728
Authors: Gautam Prasad; Theo Sottero; Xiaodong Yang; Sabine Mueller; C David James; William A Weiss; Mei-Yin Polley; Tomoko Ozawa; Mitchel S Berger; Dana T Aftab; Michael D Prados; Daphne A Haas-Kogan Journal: Neuro Oncol Date: 2011-02-11 Impact factor: 12.300
Authors: Elliot S Pohlmann; Kaya Patel; Sujuan Guo; Madeline J Dukes; Zhi Sheng; Deborah F Kelly Journal: Nano Lett Date: 2015-03-06 Impact factor: 11.189
Authors: Katrin Höland; Danielle Boller; Christian Hagel; Silvia Dolski; András Treszl; Olivier E Pardo; Paulina Cwiek; Fabiana Salm; Zaira Leni; Peter R Shepherd; Beata Styp-Rekowska; Valentin Djonov; André O von Bueren; Karl Frei; Alexandre Arcaro Journal: PLoS One Date: 2014-04-09 Impact factor: 3.240
Authors: Brittany Aguila; Adina Brett Morris; Raffaella Spina; Eli Bar; Julie Schraner; Robert Vinkler; Jason W Sohn; Scott M Welford Journal: Cancer Lett Date: 2019-08-01 Impact factor: 8.679
Authors: Paul M Daniel; Gulay Filiz; Daniel V Brown; Michael Christie; Paul M Waring; Yi Zhang; John M Haynes; Colin Pouton; Dustin Flanagan; Elizabeth Vincan; Terrance G Johns; Karen Montgomery; Wayne A Phillips; Theo Mantamadiotis Journal: Neuro Oncol Date: 2018-09-03 Impact factor: 12.300
Authors: Robin T Varghese; Sarah Young; Lily Pham; Yanping Liang; Kevin J Pridham; Sujuan Guo; Susan Murphy; Deborah F Kelly; Zhi Sheng Journal: Sci Rep Date: 2018-09-11 Impact factor: 4.379